Archivio per categoria: 4+

, , , , , , , , , , , ,

Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival

Continua a leggere
, , , , , , , , , , , , , , , , ,

EFFICACY OF DEPRESCRIBING ON HEALTH OUTCOMES: AN UMBRELLA REVIEW OF SYSTEMATIC REVIEWS WITH META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Continua a leggere
, , , , , , , , , , ,

Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody

Continua a leggere
, , , , , , , , , , , , , , ,

Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses

Continua a leggere
, , , , , , , , , , , ,

Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens

Continua a leggere
, , , , , , , , , , , ,

Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials.

Continua a leggere
, , , , , , , , , , , ,

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data

Continua a leggere
, , , , , , , , , , , , ,

First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer

Continua a leggere
, , , , , , , , , ,

Age-Adjusted Survival Extrapolations-Results May Differ From Those Generated by the Weibull Model

Continua a leggere
, , , , , , , , , ,

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median

Continua a leggere